Form 4 Filing for Altimmune, Inc. - Insider Transaction

Linda M. Richardson, Chief Commercial Officer of Altimmune, Inc., reported a series of transactions on September 16, 2026. These transactions involved 24,000 Restricted Stock Units (RSUs) which were acquired at no cost, with each RSU representing a contingent right to one share of Common Stock upon vesting. These RSUs vest over four years, with 25% vesting on September 16, 2026, and the remainder vesting in equal annual installments over the following three years, contingent on continued service. Additionally, Richardson surrendered 6,826 shares of Common Stock to the issuer to cover taxes associated with the RSU vesting, at a price of $3.24 per share. Post-transaction, Richardson holds 17,174 shares directly.